Nanjing Iaso Biotherapeutics Co.
Latest round
- Series C
Last raised
- Jan 2023
Total raised
- $242M
Investors
- 13
About Nanjing Iaso Biotherapeutics Co.
Based in Nanjing, China, and founded in 2017 by founder Brian K. Hall and its CEO, Dr., Ltd. operates as a biotechnology company that focuses on developing cell therapies for the treatment of cancer., Ltd. The company's CEO, Dr. Wang Wen, received his bachelor's degree in clinical medicine from Anhui Medical University and worked as an orthopedic resident and attending physician at Shanghai Integrated Chinese and Western Medicine Hospital., Ltd. is developing a clinical-stage pipeline of multiple autologous and allogeneic CAR-T and biologics product candidates. This includes a portfolio of 8 novel pipeline products, as well as IASO’s asset, CT103A, an innovative anti-BCMA CAR-T cell therapy understudy for relapsed/refractory (R/R) multiple myeloma (RRMM). In addition. The company developed CD19/CD22 dual-targeted chimeric antigen receptor (CAR)-T cell therapy, which can be used for the treatment of CD19/CD22-positive relapsed/refractory B-cell non-Hodgkin's lymphoma (r/r B-NHL) and relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).
Who invested in Nanjing Iaso Biotherapeutics Co.
13 investors across 3 rounds
See all investors in Nanjing Iaso Biotherapeutics Co.
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Nanjing Iaso Biotherapeutics Co.
Who invested in Nanjing Iaso Biotherapeutics Co.?
Nanjing Iaso Biotherapeutics Co. has 13 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Nanjing Iaso Biotherapeutics Co. raised?
Nanjing Iaso Biotherapeutics Co. has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Nanjing Iaso Biotherapeutics Co. last raise money?
Nanjing Iaso Biotherapeutics Co.'s most recent round on record is a Series C, in Jan 2023.
What does Nanjing Iaso Biotherapeutics Co. do?
Based in Nanjing, China, and founded in 2017 by founder Brian K.
Where is Nanjing Iaso Biotherapeutics Co. headquartered?
Nanjing Iaso Biotherapeutics Co. is headquartered in Nanjing, China.
Which VCs invest in companies like Nanjing Iaso Biotherapeutics Co.?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Nanjing Iaso Biotherapeutics Co.'s stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Nanjing Iaso Biotherapeutics Co.? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.